# Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/STXS/stereotaxis-to-participate-in-piper-sandler-37th-annual-healthcare-conference-c318e86f
Ticker: STXS
Company: Stereotaxis
Source: Stereotaxis
Published: 2025-11-24 13:58 EST
## Summary

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive...

## Article Body
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference .

David Fischel, Stereotaxis Chairman and CEO, is scheduled to participate in a fireside discussion on Wednesday, December 3 rd , 2025, at 9:00 am Eastern Standard Time and will be available that same day for one-on-one meetings.

“This is an exciting period for Stereotaxis as we achieve key regulatory milestones and demonstrate early commercial growth," said Mr. Fischel. "We look forward to engaging with investors at the Piper Sandler conference."

About Stereotaxis Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com .

This press release includes statements that may constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, including statements regarding the completion of the Company’s offering and the anticipated use of proceeds therefrom, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release. There can be no assurance that the Company will recognize revenue related to customer purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts: David L. Fischel Chairman and Chief Executive Officer

Kimberly Peery Chief Financial Officer

314-678-6100 Investors@Stereotaxis.com
## Recent Company News
- 2026-07-21 13:00 EST — [Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026](https://biopharmsignal.com/news/STXS/stereotaxis-to-report-second-quarter-2026-financial-results-on-august-11-2026-40f8033c) — Source: Stereotaxis
- 2026-07-20 12:31 EST — [University of Szeged Pioneers First Robotic Cardiology Program in Hungary](https://biopharmsignal.com/news/STXS/university-of-szeged-pioneers-first-robotic-cardiology-program-in-hungary-f69bf77d) — Source: Stereotaxis
- 2026-07-09 12:08 EST — [Stereotaxis Completes Acquisition of Robocath](https://biopharmsignal.com/news/STXS/stereotaxis-completes-acquisition-of-robocath-cf0c62e9) — Source: Stereotaxis
- 2026-05-12 20:06 EST — [Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates](https://biopharmsignal.com/news/STXS/stereotaxis-reports-2026-first-quarter-financial-results-business-updates-369195bc) — Source: Stereotaxis
- 2026-04-22 11:58 EST — [Stereotaxis Announces First MAGiC Procedures in the United States](https://biopharmsignal.com/news/STXS/stereotaxis-announces-first-magic-procedures-in-the-united-states-ae393ae4) — Source: Stereotaxis
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)